Recent advances in JAK inhibitors for the treatment of metabolic syndrome.
JAK-STAT pathway
JAKi
inflammation pharmacology
inflammation-releted diseases
metabolic syndrome
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2023
2023
Historique:
received:
23
06
2023
accepted:
11
08
2023
medline:
13
9
2023
pubmed:
13
9
2023
entrez:
13
9
2023
Statut:
epublish
Résumé
With an epidemic spread, metabolic syndrome represents an increasingly emerging risk for the population globally, and is currently recognized as a pathological entity. It is represented by a cluster of different conditions including increased blood pressure, high blood sugar, excess body fat around the waist and abnormal cholesterol or triglyceride levels. These conditions lead directly to several disorders, including obesity, dyslipidemia, hyperglycaemia, insulin resistance, impaired glucose tolerance and hypertension causing an increase in cardiovascular risk and in particular atherosclerotic disease. Despite efforts to promote healthier lifestyles through exercise, reduced caloric intake, and improved dietary choices, the incidence and prevalence of metabolic syndrome continue to rise worldwide. Recent research has highlighted the involvement of signaling pathways in chronic inflammatory conditions like obesity and type 2 diabetes mellitus, revealing the significance of the JAK/STAT pathway in atherosclerotic events. This pathway serves as a rapid membrane-to-nucleus signaling module that regulates the expression of critical mediators. Consequently, JAK inhibitors (JAKi) have emerged as potential therapeutic options for metabolic diseases, offering a promising avenue for intervention. The aim of this review is to shed light on the emerging indications of JAK inhibitors in metabolic syndrome, emphasizing their potential role in attenuating associated inflammatory processes, improving insulin sensitivity, and addressing cross-talk with the insulin pathway, with the intention of contributing to efforts in the field of inflammation pharmacology.
Identifiants
pubmed: 37701031
doi: 10.3389/fphar.2023.1245535
pii: 1245535
pmc: PMC10494544
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1245535Informations de copyright
Copyright © 2023 Collotta, Franchina, Carlucci and Collino.
Déclaration de conflit d'intérêts
VC was employed by Chemsafe S.r.l., a consultancy firm in the pharma field. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Arch Pharm Res. 2020 Nov;43(11):1173-1186
pubmed: 33161563
Int Immunol. 2000 Feb;12(2):123-32
pubmed: 10653847
J Investig Dermatol Symp Proc. 2013 Dec;16(1):S70-2
pubmed: 24326567
J Cell Mol Med. 2012 Feb;16(2):386-93
pubmed: 21447043
Eur J Pharmacol. 2021 Jul 5;902:174121
pubmed: 33901462
JAKSTAT. 2013 Oct 1;2(4):e26458
pubmed: 24416656
G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):6S-17S
pubmed: 18773746
Diabetes. 2015 Jul;64(7):2489-96
pubmed: 25732191
Diabetologia. 2016 Jan;59(1):187-196
pubmed: 26515423
Int Immunopharmacol. 2020 Mar;80:106210
pubmed: 31972425
Diabetes. 2006 Apr;55(4):942-51
pubmed: 16567515
J Biol Chem. 2003 Apr 18;278(16):13740-6
pubmed: 12560330
Int J Mol Sci. 2020 Oct 07;21(19):
pubmed: 33036382
Eur Heart J. 2021 Nov 7;42(42):4389-4400
pubmed: 34343257
Am J Nurs. 2019 Nov;119(11):20
pubmed: 31651491
Cell Commun Signal. 2017 Jun 21;15(1):23
pubmed: 28637459
SN Compr Clin Med. 2022;4(1):42
pubmed: 35079694
Arthritis Rheumatol. 2019 Sep;71(9):1450-1459
pubmed: 31385441
J Am Acad Dermatol. 2022 Jan;86(1):148-157
pubmed: 34224773
Life Sci. 2019 Dec 15;239:117045
pubmed: 31730866
J Biol Chem. 2012 Mar 23;287(13):10277-10288
pubmed: 22275361
Nat Rev Rheumatol. 2016 Jan;12(1):25-36
pubmed: 26633291
Diabetologia. 2014 May;57(5):1016-26
pubmed: 24531222
Curr Biol. 2002 Apr 2;12(7):R236-8
pubmed: 11937037
Obesity (Silver Spring). 2008 Feb;16(2):492-6
pubmed: 18239666
Signal Transduct Target Ther. 2021 Nov 26;6(1):402
pubmed: 34824210
Cleve Clin J Med. 2021 Feb 1;:
pubmed: 33526440
J Biol Chem. 2011 Jan 14;286(2):929-41
pubmed: 20980260
JCI Insight. 2017 Feb 9;2(3):e91001
pubmed: 28194444
Trends Endocrinol Metab. 2018 Jan;29(1):55-65
pubmed: 29191719
Nat Rev Nephrol. 2011 Jun;7(6):327-40
pubmed: 21537349
Mol Metab. 2020 Sep;39:101009
pubmed: 32413585
Cold Spring Harb Perspect Biol. 2018 Sep 4;10(9):
pubmed: 29038115
Sci Rep. 2017 Aug 9;7(1):7653
pubmed: 28794431
Nat Rev Rheumatol. 2017 Apr;13(4):234-243
pubmed: 28250461
Nat Rev Mol Cell Biol. 2006 Feb;7(2):85-96
pubmed: 16493415
Cell Biochem Funct. 2013 Apr;31(3):181-95
pubmed: 23335325
World J Diabetes. 2022 Jun 15;13(6):454-465
pubmed: 35800413
Cell. 2008 Oct 3;135(1):61-73
pubmed: 18854155
J Clin Invest. 2009 Feb;119(2):315-22
pubmed: 19164855
Cardiovasc Res. 2018 Jan 1;114(1):e3-e5
pubmed: 29293914
Ann Rheum Dis. 2021 Jul;80(7):865-875
pubmed: 33741556
Pharmaceutics. 2022 May 06;14(5):
pubmed: 35631587
Semin Arthritis Rheum. 2016 Dec;46(3):261-271
pubmed: 27443588
IUBMB Life. 2003 Jul;55(7):367-74
pubmed: 14584587
JAKSTAT. 2013 Apr 1;2(2):e23878
pubmed: 24058813
Nat Cell Biol. 2015 Jan;17(1):57-67
pubmed: 25487280
Peptides. 2020 Mar;125:170208
pubmed: 31759125
Front Med (Lausanne). 2022 Aug 30;9:961027
pubmed: 36111104
Int J Mol Sci. 2017 Apr 11;18(4):
pubmed: 28398233
Trends Endocrinol Metab. 2006 Nov;17(9):365-71
pubmed: 17010638
Br J Pharmacol. 2017 Sep;174(18):3018-3031
pubmed: 28646516
Front Med (Lausanne). 2021 Jul 09;8:649654
pubmed: 34307396
Nat Rev Drug Discov. 2017 Dec;16(12):843-862
pubmed: 29104284
J Allergy Clin Immunol. 2020 Oct;146(4):706-720
pubmed: 32841652
Diabetes. 2011 Oct;60(10):2474-83
pubmed: 21911747
Science. 2002 May 31;296(5573):1653-5
pubmed: 12040185
J Clin Invest. 2008 Jun;118(6):2132-47
pubmed: 18451994
FEBS J. 2016 Aug;283(16):3002-15
pubmed: 26972840
Biochem Biophys Res Commun. 2018 Jul 7;502(1):123-128
pubmed: 29787752